5

Oriental Remedies & Herbals

526989 BSE

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

1
  • Company has low interest coverage ratio.

Growth Rate

Net Income Growth
0%

Quarterly Results

Particulars Sep 2024Mar 2025Sep 2025
Sales
84
110
138
Expenses
76
78
106
Operating Profit
8
32
31
OPM %
10%
29%
23%
Other Income
0
1
2
Interest
1
1
1
Depreciation
0
0
0
PBT
8
31
31
Tax %
31%
26%
24%
Net Profit
5
23
24
EPS in Rs
18.2
13.78
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2011Mar 2012
Sales
0
0
Expenses
0.01
0.01
Operating Profit
-0.01
-0.01
Other Income
0
0
Interest
0
0
Depreciation
0
0
PBT
-0.01
-0.01
Tax %
0%
0%
Net Profit
-0.01
-0.01
Div. Payout %
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2011Mar 2012
Equity Capital
3.12
3.12
Reserves
-1.78
-1.79
Borrowings
0
0
Other Liabilities
0.03
0.04
Total Liabilities
1.37
1.37
Fixed Assets
0
0
CWIP
0
0
Investments
0.25
0.25
Other Assets
1.12
1.12
Total Assets
1.37
1.37
Figures in ₹ Crores

Cash Flow

Particulars Mar 2011Mar 2012
Operating
-0.01
-0.01
Investing
0
0
Financing
0
0
Net Cash Flow
-0.01
-0.01
Free Cash Flow
-0.01
-0.01
CFO/OP
100
100
Figures in ₹ Crores

Ratios

Particulars Mar 2011Mar 2012
ROCE %
-0.75%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Oriental Remedies & Herbals insights

25 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Shareholding Pattern

DIIs1.21%Public64.16%FIIs2.15%Promot.32.47%As ofDec 2025

Documents

1
Monitoring Agency Report 13 February 2026 - CARE report for quarter ended Dec 31, 2025 on FlySBS IPO (Rs102.53cr); minor sub-head deviations, Rs16.29cr unutilized. 13 February 2026 - CARE report for quarter ended Dec 31, 2025 on FlySBS IPO (Rs102.53cr); minor sub-head deviations, Rs16.29cr unutilized.
2
Outcome of Board Meeting 12 February 2026 - Approved monitoring report for quarter ended Dec 31, 2025; KRMM appointed internal auditor FY2025-26; recommended S.A.E. secretarial auditors. 12 February 2026 - Approved monitoring report for quarter ended Dec 31, 2025; KRMM appointed internal auditor FY2025-26; recommended S.A.E. secretarial auditors.
3
Price movement 3 February 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written … 3 February 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
4
Investor Presentation 24 January 2026 - Investor presentation filed for Jan 24, 2026 call; FY24 revenue ₹106.49 Cr, fleet expansion planned. 24 January 2026 - Investor presentation filed for Jan 24, 2026 call; FY24 revenue ₹106.49 Cr, fleet expansion planned.

Frequently Asked Questions about Oriental Remedies & Herbals

Where is Oriental Remedies & Herbals Ltd (526989) listed?
Oriental Remedies & Herbals Ltd trades under code 526989 on the BSE.
Which sector does Oriental Remedies & Herbals Ltd belong to?
Oriental Remedies & Herbals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.

Company Information

Website orhl.in
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/526989.md for Oriental Remedies & Herbals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More